| 1.17 -0.16 (-12.03%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Ocuphire Pharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to researching and bringing to market treatments for various refractive and retinal eye conditions. The company's primary investigational drug is Nyxol eye drops, a preservative-free phentolamine mesylate formulation administered once daily. Nyxol is currently undergoing advanced (Phase III) clinical trials for individuals experiencing difficulties with dim light or night vision. It is also in Phase 2b testing for reversing pharmacologically induced pupil dilation, and has successfully completed its Phase 2 VEGA-1 study for the treatment of presbyopia (age-related farsightedness). Beyond Nyxol, Ocuphire is developing APX3330, an oral tablet taken twice a day. This medication is designed to address key pathways involved in vascular diseases affecting the retina and choroid, including conditions like diabetic retinopathy and diabetic macular edema. Furthermore, the company is exploring APX2009 and APX2014, which are next-generation preclinical drug candidates and analogs derived from APX3330. Ocuphire Pharma, Inc. is based in Farmington Hills, Michigan.
Thu, 24 Oct 2024
Ocuphire Pharma Announces Acquisition of Opus Genetics - VisionMonday.com
Wed, 23 Oct 2024
Ocuphire Pharma just purchased Opus Genetics - Glance by Eyes On Eyecare
Wed, 23 Oct 2024
Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition - Fierce Biotech
Wed, 23 Oct 2024
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
Tue, 22 Oct 2024
Ocuphire Pharma acquires Opus Genetics | Eye Care Network - Modern Retina - Ophthalmology Times
Tue, 22 Oct 2024
Ocuphire Pharma Announces Acquisition of Opus Genetics - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|